FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPRO	JVAL				
OMB Number:	3235-0287				
Estimated average burd	den				
hours per response:	0.5				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

							()				/									
Name and Address of Reporting Person* Morrison Susan					2. Issuer Name and Ticker or Trading Symbol TANDEM DIABETES CARE INC [TNDM 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)															
WIOTTIS	on Susan				₁											Directo			10% O	-
(Last) (First) (Middle)			- [_	J								X	X Officer (give title below)			Other (specify below)				
C/O TANDEM DIABETES CARE, INC.				3. Date of Earliest Transaction (Month/Day/Year) 11/03/2021									EVP & Chief Admin. Officer							
11075 ROSELLE STREET			11/	11/03/2021																
110/3 ROSELLE STREET				4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable						
(Street)									•		`		,		Line)		·		,	
SAN DII	EGO C	A	92121												X	Form f	filed by One	Repo	orting Perso	n
JAN DIEGO GA J2121			_											Form filed by More than One Reporting Person				rting		
(City)	(S	tate)	(Zip)																	
		Tab	le I -	Non-Deri	vative	Sec	uritie	s A	cquir	ed, I	Dispose	d o	of, or E	Benefi	cially	Owne	d			
1. Title of	Security (Ins	tr. 3)		2. Transaction	on	2A. De	emed		3.		4. Securiti	es A	Acquired	l (A) or		5. Amo	unt of	6. 0	wnership	7. Nature
Dat			Date (Month/Day/	Year)	if any		1	Transaction Code (Instr.		D) (Instr	. 3, 4 and	Benefic Owned Report		cially (D) Following (I) ed		orm: Direct D) or Indirect I) (Instr. 4)	of Indirect Beneficial Ownership (Instr. 4)			
							ar)	8)												
								Code	v	Amount	1	(A) or (D) Price			Transaction(s) (Instr. 3 and 4)					
Common Stock 11			11/03/20)21	21			M ⁽¹⁾		5,376		A	\$18	3.86	13	13,458		D		
Common Stock			11/03/20)21				S ⁽²⁾		5,376	T	D	\$142.0	0019(3)		8,082		D		
		Т	ahle	II - Deriva	ative	Secu	rities	Δα	nuire	d Di	ennsed	οf	or Be	enefici	ally C	wned				
		•	abic								s, conve					wiicu				
1. Title of Derivative	2. Conversion			if any C		Transaction of Code (Instr. Derivative		nber							Price of	vative derivative irity Securities		10. Ownership	11. Nature	
Security	or Exercise	if any	Derivative					(Month/Day/Year)			Amount of Securities		S	curity	Form:			Beneficial		
(Instr. 3)	Price of Derivative		(Month/Day/Year)				Securities Acquired		Underlying Derivative Sec					(Instr. 5)		Beneficially Owned		Direct (D) or Indirect	Ownership (Instr. 4)	
	Security					(A) o Disp of (D		(A) or Disposed of (D)		(Instr. 3 and 4)							Following Reported	Following		' ' '
																	Transaction(s)			
						(Instr. 3, 4 and 5)											(Instr. 4)			
									Amo		unt									
														or Num	ber					
					Code	v	(A)	(D)	Date Exerc	cisable	Expiration Date	on	Title	of Sha	es					
Stock	\$18.86	11/03/2021			М		5,376			(4)	(5)		Commo	on 5,3	76	\$18.86	54,624	1	D	

Explanation of Responses:

- Represents shares of common stock received upon exercise of a stock option award.
- $2. \ The \ shares \ were \ sold \ pursuant \ to \ a \ Rule \ 10b5-1 \ trading \ plan \ adopted \ by \ the \ Reporting \ Person \ on \ August \ 6, \ 2021.$
- 3. The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between \$142.00 to \$142.03. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold.
- 4. The options vested as to fifty (50%) of the underlying shares on 6/14/2019, and the remaining shares vested in twelve (12) equal monthly installments thereafter, subject to the terms of Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the "2013 Plan").
- 5. The expiration date for these options is 10 years from the date of grant.

Remarks:

s/ David B. Berger, Attorneyin-Fact for Susan M. Morrison

11/05/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.